期刊导航

论文摘要

基于YTHDC2、IGF2BP2和HNRNPC的头颈部鳞状细胞癌N6-甲基腺苷风险模型构建及临床应用评估

Construction and clinical evaluation of N6-methyladenosine risk signature of YTHDC2, IGF2BP2, and HNRNPC in head and neck squamous cell carcinoma

作者:岳蔷薇, 徐乐, 张东升

Author:Yue Qiangwei, Xu Le, Zhang Dongsheng.

收稿日期:2022-02-21          年卷(期)页码:2022,40(6):704-704-709

期刊名称:华西口腔医学杂志

Journal Name:West China Journal of Stomatology

关键字:头颈部鳞状细胞癌,N6-甲基腺苷,预后风险模型,肿瘤免疫微环境,生物信息学分析,

Key words:head and neck squamous cell carcinoma,N6-methyladenosine,prognostic risk signature,tumor immune microenvironment,bioinformatic analysis,

基金项目:山东省自然科学基金面上项目(ZR2021MH353)

中文摘要

目的 利用生物信息学技术构建头颈部鳞状细胞癌(HNSCC)N6-甲基腺苷(m6A)调节因子模型,进行预后及肿瘤免疫微环境评估。 方法 利用R语言对癌症基因组图谱(TCGA)数据库HNSCC患者进行m6A调节因子风险预后模型构建,然后对不同风险组进行差异基因分析、细胞类型富集分析和临床相关性分析。 结果 HNSCC中15个m6A调节因子表达异常,根据异常表达基因构建了HNSCC YTHDC2、IGF2BP2和HNRNPC三基因独立预后风险模型,其中高风险组免疫抑制相关因子及免疫细胞显著增多,抗肿瘤免疫相关因子及免疫细胞减少,呈现促肿瘤的免疫微环境。 结论 联合YTHDC2、IGF2BP2和HNRNPC的m6A调节因子风险预后模型可以有效评估HNSCC患者预后及肿瘤免疫浸润状态。

英文摘要

ObjectiveThis work aimed to construct N6-methyladenosine (m6A) regulator-based prognostic signature and evaluate the prognostic value and the intervention on tumor immune microenvironment of this m6A risk signature.MethodsUsing transcriptome and clinical data of head and neck squamous cell carcinoma (HNSCC) from The Cancer Genome Atlas (TCGA), we profiled m6A regulators and constructed an m6A risk signature. The relationship between m6A modulation and immune function was studied by differential gene expression, cell type enrichment, and correlation analyses.ResultsFifteen m6A regulators had aberrant expression in HNSCC. A three-gene m6A prognostic signature (i.e., YTHDC2, IGF2BP2, and HNRNPC) was constructed and identified as an independent prognostic indicator for HNSCC. The m6A regulator signature-based high-risk group revealed pro-tumoral immune microenvironment due to the dysregulation of immune-related gene expression, abnormal enrichment of multiple immunocytes, and production of immunoregulatory factors.ConclusionThis comprehensive analysis of m6A regulators and tumor immune landscape in HNSCC revealed that the m6A signature of YTHDC2, IGF2BP2, and HNRNPC could serve as a promising biomarker for monitoring HNSCC development and may be a potential target for tumor therapy in the future.

上一条:无托槽隐形矫治进展评估功能的准确性研究

关闭

Copyright © 2020四川大学期刊社 版权所有.

地址:成都市一环路南一段24号

邮编:610065